January 9, 2025 10:19 AM ESTUpdated 11:25 AM
News Briefing

Num­ab ex­tends its Se­ries C; AnaC­ar­dio rais­es $19M for its heart fail­ure drug

ENDPOINTS

Plus, news about Rheuma­Gen and Ry­bo­Dyn:

Num­ab Ther­a­peu­tics brings in $55M: The Swiss biotech ex­tend­ed its Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

In­tel­lia to cut work­force by 27%, plans com­mer­cial­iza­tion of first CRISPR ther­a­py in 2027

A service from the Financial Times